The universal definition of myocardial infarction includes the increase and/or decrease in cardiac biomarkers, with at least 1 value greater than the 99th-percentile upper reference limit, concurrently with evidence of myocardial ischemia and corresponding clinical symptoms, electrocardiographic changes, or imaging evidence (1 ) . Among cardiac biomarkers, cardiac troponins, including cardiac troponin I (cTnI) 1 and cardiac troponin T (cTnT), have become the gold standard. Several noncardiac etiologies for increases in cardiac troponins have been described, however (2 ) , and discordant values for cTnT and cTnI have been encountered in the clinical setting. The aim of our study was to systematically compare a cTnT assay and a cTnI assay with regard to discrepant values. This study was conducted in accord with the World Medical Association Declaration of Helsinki (3 ) .
We used the Architect cTnI STAT Troponin-I assay (Abbott Diagnostics) and the new high sensitive troponin T (hsTnT) assay (Troponin T hs) on the Modular Analytics system (Roche Diagnostics) to make 9004 simultaneous cTnI and cTnT measurements on 3995 patients and then analyzed the data.
Because we were concerned about major discrepancies, we used 0.032 g/L as the cutoff value for both the cTnI and hsTnT measurements. After applying this cutoff to our samples, we found that 1037 samples from 664 patients had inconsistent cTnI and hsTnT results. The majority of the discrepant results were explained by minor differences near the cutoff or by differences in cardiac troponin kinetics.
To exclude minor inconsistencies, we filtered our database to retain only entries in which a result for one of the cardiac troponin assays was below the 0.032-g/L cutoff value and the result for the other assay was Ͼ0.096 g/L (i.e., 3 times the cutoff value). This filtering produced 128 discrepant pairs of results, from 83 cases. To minimize the possibility of measurement discordance attributable to dynamic differences or sampling errors, we examined only cases of discrepant results that were confirmed by at least one additional measurement from a separate blood sample collected during the same hospital stay. This second filtering step produced 18 cases, which we evaluated in detail.
Nine of the 18 cases had cTnI concentrations above and hsTnT concentrations below our cutoffs (Table 1 , case nos. 1-9). The primary clinical diagnoses in this group were acute coronary syndrome (ACS) (n ϭ 2), coronary artery disease without ACS (n ϭ 4), hypertension (n ϭ 5), atrial fibrillation (n ϭ 1), respiratory diseases (n ϭ 4), muscular damage (n ϭ 2), inflammatory diseases (n ϭ 2), type 2 diabetes mellitus (n ϭ 3), and renal failure (n ϭ 1). Four patients underwent coronary angiography, but discordant values had already been observed before the procedure.
Nine patients had hsTnT concentrations above the threshold and cTnI concentrations below the threshold (Table 1 , case nos. 10 -18). None of these patients had received an ACS diagnosis. The primary clinical diagnoses in this group were coronary artery disease (n ϭ 3), atrial fibrillation (n ϭ 2), renal failure (n ϭ 5), respiratory diseases (n ϭ 7), inflammatory disorders (n ϭ 3), type 2 diabetes mellitus (n ϭ 4), chest trauma (n ϭ 1), malignancy (n ϭ 1), and dermatomyositis (n ϭ 1). Coronary angiography was performed in 2 patients who had marked differences in cardiac troponin values before the intervention. Two patients in this group died during the hospital stay, from respiratory failure and cardiorespiratory failure. One individual was healthy with no sign of illness. Thus, diagnoses of coronary artery disease, with or without ACS, tended to be more frequent in the high-cTnI group, whereas diagnoses of renal insufficiency tended to be more common in the high-hsTnT group, but these differences were not statistically significant (P Ͼ 0.05). When we used the 99th percentiles provided by the manufacturers (0.022, 0.009, and 0.014 g/L for cTnI males, cTnI females, and hsTnT males and females, respectively), the cTnI values for 7 individuals in the highhsTnT group and the hsTnT values for 2 individuals in the high-cTnI group were below this cutoff.
Increases of cardiac troponins in conditions other than ACS have been well established (2 ); however, the discrepancies between cTnT and cTnI are less well documented and understood. Differences in cTnI and cTnT kinetics due to variations in clearance rates, especially in patients with renal failure, can be a possible cause (4 ) . Furthermore, the degradation of cardiac troponins to antigenic structures that alter analytical detection also may play a role. Recently, autoantibodies against cardiac troponins with possible negative (interfering) or positive (stabilizing) effects on troponin measurements have been described. In one study, 11% of individuals with cardiac troponin antibodies had antibodies directed against both cTnT and cTnI (5 ) . Hence, such autoantibodies can af-fect cTnT measurements, cTnI measurements, or both. Because we were unable to identify a common clinical denominator in the high-hsTnT group or the highcTnI group, we suspect that autoantibodies directed against cardiac troponins contributed to the severely discrepant cTnI and hsTnT measurements in our patients, but we cannot prove this hypothesis owing to the retrospective study design. Irrespective of the mechanisms involved and despite their rare occurrence, the differences in cTnI and hsTnT values of this magnitude that we obtained with these reliable assays were unexpected. It therefore might be helpful to confirm clinically equivocal increases or results unexpectedly below the cutoff value, obtained for one cardiac troponin by measuring the other. 
Role of Sponsor:
The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript. 
Full COLD-PCR Protocol for Noninvasive Prenatal Diagnosis of Genetic Diseases
To the Editor:
After the discovery of fetal DNA in maternal plasma, investigators reported different strategies for the noninvasive prenatal diagnosis of genetic diseases (1 ) . Despite the advances in improving the analytical sensitivity of methods, distinguishing between fetal and maternal sequences remains very challenging, and the field of noninvasive prenatal diagnosis of genetic diseases has yet to attain a routine application in clinical diagnostics. An innovative strategy that has been reported is based on COLD-PCR (coamplification at a lower denaturation temperature PCR), 1 which exploits melting temperature (T m ) differences between variant or mismatched sequences and wild-type sequences. This approach uses a critical denaturation temperature (T c ) lower than the T m to selectively amplify minority mutated alleles (2 ) . We have developed assays for the identification of fetal paternally inherited mutations in maternal plasma. These assays use full COLD-PCR for the detection of IVSI.110 (GϾA) and Cd39 (CϾT) HBB (globin, beta) gene mutations that cause ␤-thalassemia.
Full COLD-PCR is based on the generation of heteroduplexes between mutant and wild-type sequences. These heteroduplexes melt at lower temperatures than the wild-type homoduplexes. They are selectively denatured at the T c and then subsequently amplified. Given that both the fetal and maternal DNA content in maternal plasma has been demonstrated to vary from pregnancy to pregnancy (3 ), we used a range of T c values and several replicates of the same sample to develop a protocol that was specific for the identification of each mutation. To simplify the T c evaluation, we amplified plasma DNA from wild-type controls with a conventional PCR protocol and several replicates of the same sample and varied the denaturation temperature. The lowest denaturation temperature that still allowed amplification of wild-type samples (81.9°C for IVSI.110, 83.8°C for Cd39) was chosen as the upper limit of a T c interval, which spanned 1°C. We scaled the denaturation temperatures for 8 replicates of the maternal plasma sample down by increments of 0.1°C-0.2°C, beginning with the upper T c value identified. The use of a range of potential T c values with several replicates instead of a single T c ensured that at least 1 replicate exhibited differential denaturation of mutant and wild-type alleles, thereby allowing robust PCR amplification.
The study was approved by the local ethics review boards. After obtaining written informed consent from couples in which the parents carried different mutations, we collected 6 mL of maternal blood before chorionic villus sampling. DNA was extracted from 500 L of plasma (4 ) and eluted in a 60-L volume. COLD-PCR was performed in a 25-L final volume containing 5 L of eluted DNA, 200 mol/L of each deoxynucleoside triphosphate, 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 1.5 U of FastStart Taq DNA polymerase (Roche Applied Science), and 10 pmol of each primer. Cycling conditions were as follows: 95°C for 4 min; 25 cycles of 95°C for 15 s, 54°C for 30 s, and 72°C for 1 min; 72°C for 10 min; 95°C for 4 min; 35 cycles of 95°C for 15 s, 70°C for 8 min (to generate heteroduplexes), specific T c temperature for 3 s, and 72°C for 1 min; 72°C for 7 min. For IVSI.110, the T c interval was 81.9°C-80.9°C; for Cd39, the T c interval was 83.8°C-82.8°C. The amplification primers for IVSI.110 were 5Ј-TAAGGAGAC CAATAGAAACT-3Ј (forward) and 5Ј-GTAGACCACCAGCAGC-3Ј (reverse); the amplicon size was 119 bp. The primers for Cd39 were 5Ј-GTCTATTTTCCCACCCTT-3Ј (forward) and 5Ј-AGCACTTTCTTG
